Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivermectin and Iota-carrageenan prophylaxis for COVID-19 in healthcare workers
NCT04701710Phase 2Completed
- Start
- Oct 2020
- Primary completion
- Dec 2020
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CHILD-IVITAB and Iota-carrageenan in coronavirus disease 2019 (COVID-19) (2 arms). Primary endpoint: Number of subjects diagnosed with COVID-19 at 4 weeks. Started Oct 2020; status: completed.
02
Drugs
CHILD-IVITABIota-carrageenan
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04701710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04701710.